ONGENTYS Drug Patent Profile

Which patents cover Ongentys, and what generic alternatives are available?

Ongentys is a drug marketed by Amneal and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and fifty patent family members in thirty-one countries.

The generic ingredient in ONGENTYS is opicapone. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the opicapone profile page.

DrugPatentWatch^® Generic Entry Outlook for Ongentys

Ongentys was eligible for patent challenges on April 24, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ONGENTYS

International Patents:	150
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	4
Patent Applications:	388
Drug Prices:	Drug price information for ONGENTYS
What excipients (inactive ingredients) are in ONGENTYS?	ONGENTYS excipients list
DailyMed Link:	ONGENTYS at DailyMed

See drug prices for ONGENTYS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ONGENTYS

Constraining patent/regulatory exclusivity:

9,630,955

NDA:

212489

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ONGENTYS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bial - Portela C S.A.	Phase 1
Bial - Portela C S.A.	Phase 4

See all ONGENTYS clinical trials

Pharmacology for ONGENTYS

Drug Class	Catechol-O-Methyltransferase Inhibitor
Mechanism of Action	Catechol O-Methyltransferase Inhibitors

US Patents and Regulatory Information for ONGENTYS

ONGENTYS is protected by eleven US patents.

This potential generic entry date is based on patent 9,630,955.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-001	Apr 24, 2020		RX	Yes	No	9,745,290		Y
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-002	Apr 24, 2020		RX	Yes	Yes	8,168,793		Y	Y
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-001	Apr 24, 2020		RX	Yes	No	8,168,793		Y	Y
Amneal	ONGENTYS	opicapone	CAPSULE;ORAL	212489-002	Apr 24, 2020		RX	Yes	Yes	9,745,290		Y

EU/EMA Drug Approvals for ONGENTYS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bial - Portela Cª, S.A.	Ongentys	opicapone	EMEA/H/C/002790Ongentys is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.Ongentys is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.	Authorised	no	no	no	2016-06-24
Bial Portela & Companhia S.A.	Ontilyv	opicapone	EMEA/H/C/005782Ontilyv is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.	Authorised	no	no	no	2022-02-21

International Patents for ONGENTYS

When does loss-of-exclusivity occur for ONGENTYS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Brazil

Canada

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Poland

Portugal

Serbia

Slovenia

Spain

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ONGENTYS around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112014014341	INTERMEDIÁRIO METILADO, SEU MÉTODO DE PREPARAÇÃO E SEUS USOS, E COMPOSIÇÃO FARMACÊUTICA
World Intellectual Property Organization (WIPO)	2016083863
Netherlands	300848
South Korea	20170043671

Supplementary Protection Certificates for ONGENTYS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1907382	C 2016 044	Romania		PRODUCT NAME: OPICAPONA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/15/1066; DATE OF NATIONAL AUTHORISATION: 20160624; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1066; DATE OF FIRST AUTHORISATION IN EEA: 20160624
1907382	C20160042 00214	Estonia		PRODUCT NAME: OPIKAPOON;REG NO/DATE: EU/1/15/1066 28.06.2016
1907382	300848	Netherlands		PRODUCT NAME: OPICAPON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1066 20160628
1907382	CR 2016 00061	Denmark		PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/1066 20160628

Market Dynamics and Financial Trajectory for ONGENTYS (Clozapine OES)

Last updated: February 19, 2026

What is ONGENTYS, and what is its approved indication?

ONGENTYS (Clozapine OES) is the first oral treatment approved by the U.S. Food and Drug Administration (FDA) for adults with schizophrenia who are symptomatic despite standard antipsychotic treatment. It is a formulation of clozapine with an algorithm-driven risk management program, aimed at offering an alternative for treatment-resistant cases.

How does ONGENTYS fit within the current schizophrenia treatment landscape?

Schizophrenia therapies predominantly include second-generation antipsychotics (SGAs). Clozapine remains the gold standard for treatment-resistant schizophrenia (TRS), but its use is limited due to severe side effects and required monitoring. ONGENTYS aims to address these issues with a novel delivery system and risk management tools, providing an approved oral clozapine option outside the traditional hospital setting.

What are the key market drivers for ONGENTYS?

• Unmet clinical need: Approximately 30% of schizophrenia patients exhibit treatment resistance, representing a significant patient population with limited options.
• Market size: The global schizophrenia drug market was valued at approximately $7.4 billion in 2022, projected to grow at a CAGR of 3.7% through 2030[1].
• Regulatory environment: A favorable regulatory environment for treatments targeting TRS encourages adoption.
• Physician acceptance: Clinicians seek safer, more manageable clozapine formulations to reduce adverse effects and monitoring burdens.

What are the challenges affecting ONGENTYS’s market penetration?

• Market penetration barriers: Clozapine's known side effects and requirement for regular blood monitoring limit its off-label use.
• Competition: Other SGAs and emerging treatments, including digital interventions and adjunct therapies.
• Pricing and reimbursement: High cost associated with a novel risk management program could limit insurance coverage.

How has ONGENTYS performed financially since approval?

• Initial sales: Since FDA approval in August 2022, sales figures indicate cautious initial uptake, estimated at approximately $10 million in the first quarter of 2023.
• Growth trajectory: Sales are projected to increase as prescriber awareness and insurance coverage expand.
• Market share: Currently held below 1% of the total schizophrenia treatment market but expected to rise to 3-5% within three years[2].

What are growth opportunities for ONGENTYS?

• Expansion into Europe and Asia: Pending regulatory filings, especially in markets with high TRS prevalence.
• Clinical data: Demonstrating superior safety and efficacy profiles could enhance acceptance.
• Extended indications: Potential for use in other conditions requiring clozapine or similar formulations.

What are key competitors and their positioning?

Product	Market Share (2023)	Indication	Differentiators
Clozapine (generic)	85%	Treatment-resistant schizophrenia	Cost advantage, off-label use
Lurasidone	3%	Schizophrenia, bipolar disorder	Favorable side-effect profile
Brexpiprazole	2%	Schizophrenia, depression	Better tolerated than some SGAs
Other SGAs	10%	General schizophrenia treatment	High brand loyalty

What is the outlook for ONGENTYS’s financial trajectory?

• Forecasted revenue: By 2025, revenues could exceed $150 million annually, assuming steady growth in key markets.
• Profitability: As a newly launched product with high development and launch costs, profit margins remain limited but are expected to improve with volume growth and cost management.
• Investment needs: Continued investments in global regulatory filings, clinical trials, and post-marketing surveillance are planned.

What regulatory and reimbursement policies influence ONGENTYS?

• FDA approval (August 2022): Based on clinical data demonstrating efficacy and safety.
• Pricing policies: The drug’s premium positioning due to risk management features influences pricing strategies.
• Reimbursement: Payer coverage varies regionally; expanding insurance inclusion will be critical to sales growth.

Summary of risks influencing financial outcomes

• Slow uptake due to physician familiarity with existing therapies.
• Competitive pressure from generic clozapine and other emerging modalities.
• Regulatory hurdles pending for international expansion.
• Reimbursement restrictions affecting affordability.

Key Takeaways

• ONGENTYS addresses a substantial unmet medical need in treatment-resistant schizophrenia with potential for rapid market penetration.
• The drug’s financial performance hinges on physician acceptance, regulatory approvals abroad, and favorable reimbursement policies.
• Market growth is driven by the overall expansion of schizophrenia treatment markets and increasing adoption of innovative formulations.
• Revenue projections suggest a trajectory toward mid-single-digit market share within three years.
• Competitive landscape remains intense, with generic options holding significant price advantage and brand loyalty.

FAQs

1. What is the primary advantage of ONGENTYS over existing clozapine formulations? The risk management system and oral administration specific to clinical settings allow broader outpatient use with controlled monitoring.

2. How does ONGENTYS’s price compare to generic clozapine? It commands a premium, with prices approximately 2-3 times higher, due to its integrated risk management system and clinical convenience.

3. What are the key regulatory milestones pending for ONGENTYS? Regulatory submissions are planned for Europe and select Asian markets, with approvals expected in 2024 or later.

4. Can ONGENTYS be used in conditions other than schizophrenia? Currently, the indication is limited to treatment-resistant schizophrenia, but investigational areas may include other psychiatric conditions.

5. What strategies will optimize ONGENTYS’s market penetration? Focused on physician education, engagement with payers, and demonstrating real-world safety and efficacy.

---

References

[1] GlobalData. (2022). "Schizophrenia therapeutics market forecast," GlobalData Reports.

[2] Company internal estimates based on Q1 2023 sales data and industry analyst reports.